We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Philip McCarthy MD

Philip L. McCarthy MD

Professor of Oncology and Internal Medicine; Director Emeritus, Transplant and Cellular Therapy Program, Department of Medicine at Roswell Park Comprehensive Cancer Center/SUNY, Buffalo, New York

Philip L. McCarthy, MD, is a Professor of Oncology and Internal Medicine, Director Emeritus of the Transplant and Cellular Therapy (TCT) Program, and a member of the Department of Medicine at Roswell Park Comprehensive Cancer Center/SUNY at Buffalo.

Dr. McCarthy’s research interests are devoted to developing novel intensive and reduced intensity allogeneic and autologous hematopoietic stem cell transplant (HSCT) approaches for the treatment of hematologic disorders, leading to improved patient outcomes and decreased toxicity. He has over 25 years of experience treating patients with hematologic disorders, directing clinical and translational studies with a particular interest in multiple myeloma (MM).

Dr. McCarthy has served as chair, or co-chair, of several clinical trials, including CALGB 100104, a phase III clinical trial evaluating lenalidomide maintenance after autologous HSCT for MM. This study demonstrated an improved progression-free and overall survival for MM patients receiving lenalidomide maintenance therapy after autologous HSCT. Dr. McCarthy facilitates the development of translational research projects that will lead to advances in the utilization of cellular therapy including immune effector cell treatment and allogeneic (allo) HCT as well as developing strategies for the early, successful treatment of hematologic malignancies.


No disclosures are reported.